The DOI matches its Crossref record; 275 of the 275 references it cites were found in a registry or an index.
European Evidence‐based (S3) Guidelines for the Treatment of Acne
Abstract
Nasty/Rzany An evidence-based guideline has been defined as 'a systematically developed statement that assists clinicians and patients in making decisions about appropriate treatment for a specific condition'.1 A guideline will never encompass therapy specifications for all medical decision-making situations. Deviation from the recommendations may, therefore, be justified in specific situations. This is not a textbook on acne, nor a complete, all-inclusive reference on all aspects important to the treatment of acne. The presentation on safety in particular is limited to the information available in the included clinical trials and does not represent all the available and necessary information for the treatment of patients. Additional consultation of specific sources of information on the particular intervention prescribed (e.g. product information sheet) is necessary. Furthermore, all patients should be informed about the specific risks associated with any given topical and/or systemic therapy. Readers must carefully check the information in this guideline and determine whether the recommendations contained therein (e.g. regarding dose, dosing regimens, contraindications, or drug interactions) are complete, correct, and up-to-date. The authors and publishers can take no responsibility for dosage or treatment decisions. Improvement in the care of acne patients The idea behind this guideline is that recommendations based on a systematic review of the literature and a structured consensus process will improve the quality of acne therapy in general. Personal experiences and traded therapy concepts should be critically evaluated and replaced, if applicable, with the consented therapeutic recommendations. In particular, a correct choice of therapy should be facilitated by presenting the suitable therapy options in a therapy algorithm, taking into account the type of acne and the severity of the disease. Reduction of serious conditions and scarring As a result of the detailed description of systemic therapies for patients with severe acne, reservations about these interventions should be overcome to ensure that patients receive the optimal therapy. With the timely introduction of sufficient therapies, the development of serious post-acne conditions and severe scarring should be reduced. Promotion of adherence Good therapeutic adherence is key to treatment success. Adherence is facilitated by knowledge of the product being used, for example treatment duration, the expected onset of effect, the sequence of the healing process, the maximal achievable average effect, expected adverse events and the benefit to quality of life. Reduction of antibiotic resistance The use of topical and systemic antibiotics should be optimized by using appropriate combinations for a predefined duration, to reduce the development of antibiotic resistance. Health care professionals This guideline has been developed to help health care professionals provide optimal therapy to patients with mild, moderate or severe acne. The primary target groups are dermatologists and other professionals involved in the treatment of acne, such as paediatricians and general practitioners. The target group may vary with respect to national differences in the distribution of services provided by specialists or general practitioners. Patients The recommendations of the guideline refer to patients who suffer from acne. These are mainly adolescents treated in outpatient clinics. The appropriate therapy option is presented according to the type of acne that is present. The primary focus is the induction therapy of facial acne (see Chapter 1.6). Non-primary target groups are patients with special forms of acne, such as, occupational acne, chloracne, acne aestivalis, acne neonatorum, acne inverse (hidradenitis suppurativa). European guidelines are intended for adaptation to national conditions. It is beyond the scope of this guideline to take into consideration the specific costs and reimbursement situations in every European country. Differences in prices, reimbursement systems, willingness and ability to pay for medication among patients and the availability of generics are too large. Therefore, pharmacoeconomic considerations will have to be taken into account when guidelines are developed at national and local levels. The personal financial and health insurance situation of a patient may necessitate amendments to the prioritization of treatment recommendations. However, if financial resources allow, the suggested ranking in the therapeutic algorithm should be pursued. The skin type and stage of disease has to be taken into consideration when choosing the vehicle for topical treatments. The efficacy and safety/tolerability of topical treatments are largely influenced by the choice of vehicle. The face is the primary region of interest for the treatment of acne. Appearance, scarring, quality of life and social stigmatization are important considerations when dealin
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–275 of 275
Glass, D., Boorman, G. C., Stables, G. I., et al. (1999) · Dermatology · doi:10.1159/000018255 · Cited by 36
Topical Erythromycin vs Blank Vehicle in a Multiclinic Acne Study
Jones, E. L. (1981) · Archives of Dermatology · doi:10.1001/archderm.1981.01650090033020 · Cited by 36
Alirezaï, M., George, S. A., Coutts, I., Roseeuw, D. I., Hachem, J. P., Kerrouche, N., Sidou, F., & Soto, P. (2007) · PubMed · doi:10.1684/ejd.2007.0188 · Cited by 36
Thiboutot, D. M., Gold, M. H., Jarratt, M., Kang, S., Kaplan, D. L., Millikan, L. E., Wolfe, J., Loesche, C., & Baker, M. (2001) · PubMed · Cited by 36
Ellis, C. N., Leyden, J., Katz, H. I., Goldfarb, M., Hickman, J., Jones, T. M., & Tschen, E. H. (2001) · PubMed · Cited by 35
Gupta, A. K., Lynde, C. W., Kunynetz, R., Amin, S., Choi, K. L., & Goldstein, E. (2003) · Journal of Cutaneous Medicine and Surgery · doi:10.1007/s10227-002-2101-2 · Cited by 35
[13-cis retinoic acid in the oral therapy of acne conglobata. Results of a multi-center study].
Plewig, G., Gollnick, H. P. M., Meigel, W., & Wokalek, H. (1981) · PubMed · Cited by 35
Self-citationHörfelt, C., Stenquist, B., Halldin, C. B., Ericson, M. B., & Wennberg, A.-M. (2009) · Acta Dermato Venereologica · doi:10.2340/00015555-0667 · Cited by 34
Fugère, P., Percival-Smith, R. K. L., Lussier‐Cacan, S., Davignon, J., & Farquhar, D. (1990) · Contraception · doi:10.1016/0010-7824(90)90106-6 · Cited by 34
Vartiainen, M., de Gezelle, H., & Broekmeulen, C. J. H. (2001) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/ejc.6.1.46.53 · Cited by 34
Double-Blind Study of Doxycycline in Acne Vulgaris
Plewig, G. (1970) · Archives of Dermatology · doi:10.1001/archderm.1970.04000040057011 · Cited by 33
A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris
Swinyer, L. J., Baker, M. D., Swinyer, T., & Mills, O. H. (1988) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1988.tb03472.x · Cited by 32
Isotretinoin and Tetracycline in the Management of Severe Nodulocystic Acne
Lester, R. S., Schachter, G. D., & Light, M. J. (1985) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1985.tb05775.x · Cited by 32
Wang, S. Q., Counters, J., FLOR, M. E., & Zelickson, B. D. (2006) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2006.32042.x · Cited by 31
Berger, R. S., Rizer, R. L., Barba, A., Wilson, D., Stewart, D. M., Grossman, R., Nighland, M., & Weiss, J. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.021 · Cited by 31
The effect of benzoyl peroxide on acne
Cunliffe, W., & Holland, K. (1981) · Acta Dermato Venereologica · doi:10.2340/0001555561267269 · Cited by 31
Cunliffe, W. J., Fernandez, C., Bojar, R. A., Kanis, R., West, F., & The Zindaclin Clinical Study Group (2005) · Journal of Dermatological Treatment · doi:10.1080/09546630500281957 · Cited by 30
Siadat, A. H., Baradaran, E. H., Moradi, S., & Nilfroushzadeh, M. A. (2009) · Indian Journal of Dermatology Venereology and Leprology · doi:10.4103/0378-6323.51247 · Cited by 30
Minocycline therapy in acne vulgaris.
Cullen, S. I., & Cohan, R. H. (1976) · PubMed · Cited by 30
Ko, H., Song, M., Seo, S., Oh, C., Kwon, K., & Kim, M. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2008.02920.x · Cited by 29
Lim, D. S., & MURPHY, G. M. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05389.x · Cited by 29
(2006) · PubMed · Cited by 28
AN OPEN STUDY OF TRIPHASIL AND DIANE 50 IN THE TREATMENT OF ACNE
Wishart, J. (1991) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.1991.tb00683.x · Cited by 28
Dieben, T. O. M., Vromans, L., Theeuwes, A., & Bennink, H. J. T. C. (1994) · Contraception · doi:10.1016/0010-7824(94)90024-8 · Cited by 28
Berger, R. S., Barba, A., Fleischer, A. B., Leyden, J. J., Lucky, A. W., Pariser, D. M., Rafal, E. S., Thiboutot, D. M., Wilson, D. J., Grossman, R., et al. (2007) · PubMed · Cited by 28
Borglund, E., Hägermark, Ö., & Nord, C. E. (1984) · PubMed · Cited by 28
Pariser, D. M., Thiboutot, D. M., Clark, S. D., Jones, T. M., Liu, Y., & Graeber, M. (2005) · PubMed · Cited by 28
Bowman, S. M., Gold, M. H., Nasir, A., & Vamvakias, G. (2005) · PubMed · Cited by 26
Halbe, H. W., de Melo, N. R., Bahamondes, L. G., Petracco, Á., Lemgruber, M., de Andrade, R. P., da Cunha, D. C., Guazelli, C., & Baracat, E. C. (1998) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625189809051413 · Cited by 26
Water-based versus alcohol-based benzoyl peroxide preparations in the treatment of acne vulgaris
Fyrand, O., & Bang Jakobsen, H. (2009) · Dermatologica · doi:10.1159/000249352 · Cited by 25
Topical clindamycin versus oral tetracycline and placebo in acne vulgaris.
Lr, B. (1984) · PubMed · Cited by 25
Dhir, R., Gehi, N., Agarwal, R., & More, Y. E. (2008) · Indian Journal of Dermatology Venereology and Leprology · doi:10.4103/0378-6323.39727 · Cited by 25
Effect of a desogestrel-containing oral contraceptive on the skin
Katz, H. I., Kempers, S. E., Akin, M., DUNLAP, F. E., Whiting, D., & Norbart, T. C. J. (2000) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625180008500411 · Cited by 25
THE COMBINED USE OF TOPICAL BENZOYL PEROXIDE AND TRETINOIN IN THE TREATMENT OF ACNE VULGARIS
Handojo, I. (1979) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1979.tb01956.x · Cited by 25
Benzoyl Peroxide, Adapalene, and Their Combination in the Treatment of Acne Vulgaris
Korkut, C., & Pişkin, S. (2005) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2005.tb00739.x · Cited by 24
Marazzi, P., Boorman, G., Donald, A., & Davies, H. (2002) · Journal of Dermatological Treatment · doi:10.1080/09546630260199460 · Cited by 24
Lucky, A. W., Jorizzo, J. L., Rodriguez, D., Jones, T. M., Stewart, D. M., Tschen, E. H., Kanof, N. B., Miller, B. H., Wilson, D. C., & Loven, K. H. (2001) · PubMed · Cited by 23
Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris.
Krishnan, G. (1976) · PubMed · Cited by 23
Long-term treatment of acne with 20% azelaic acid cream.
Cavicchini, S., & Caputo, R. (1989) · PubMed · Cited by 22
Topical Tetracycline Hydrochloride vs. Topical Clindamycin Phosphate in the Treatment of Acne
Padilla, R. S., Mccabe, J. M., & Becker, L. E. (1981) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1981.tb02013.x · Cited by 22
Kuhlman, D. S., & Callen, J. P. (1986) · PubMed · Cited by 22
Isotretinoin versus Minocycline in Cystic Acne: A Study of Lipid Metabolism
Pigatto, P. D. M., Finzi, A. F., Altomare, G. F., Polenghi, M. M., Vergani, C., & Vigotti, G. (2009) · Dermatologica · doi:10.1159/000249321 · Cited by 21
WEBSTER, G. F., Cargill, D. I., Quiring, J. N., et al. (2009) · PubMed · Cited by 21
The Natural Evolution of Comedones Into Inflammatory Papules and Pustules
Orentreich∥, N., & Durr, N. P. (1974) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12724274 · Cited by 20
Dubertret, L., Alirezaï, M., Rostain, G., et al. (2003) · PubMed · Cited by 20
Thiboutot, D. M., Jarratt, M., Rich, P. A., Rist, T. E., Rodriguez, D. A., & Levy, S. F. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85151-7 · Cited by 19
Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris
Monk, B. E., ALMEYDA, J. A., Caldwell, I. W., GREEN, B., Pelta, D. E., LEONARD, J. N., du Vivier, A. W. P., JOHNSON, K., & Tolowinska, I. (1987) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1987.tb02499.x · Cited by 19
Doxycycline versus minocycline in the treatment of acne vulgaris: A double-blind study
Ólafsson, J., Gudgeirsson, J., Eggertsdóttir, G. E., et al. (1989) · Journal of Dermatological Treatment · doi:10.3109/09546638909086681 · Cited by 19
Erythromycin 2 percent gel in the treatment of acne vulgaris.
Pochi, P. E., Bagatell, F. K., Ellis, C. N., Stoughton, R. B., Cg, W., Gd, S., & Sefton, J. (1988) · PubMed · Cited by 19
Dose-Response Relationship in Isotretinoin Therapy for Conglobate Acne
van der Meeren, H. L. M., van der Schroeff, J. G., Stijnen, T., van Duren, J. A., van der Dries, H. A. C., & Vader, P. C. V. V. (2009) · Dermatologica · doi:10.1159/000249803 · Cited by 18
WEBSTER, G. F., Rich, P. A., Gold, M. H., Mraz‐Gernhard, S., Calvarese, B. M., & Chen, D. A. (2009) · PubMed · Cited by 18
A comparison of Cleocin T Solution, Cleocin T Gel, and placebo in the treatment of acne vulgaris.
Ellis, C. N., Wr, G., Dz, S., & Jl, H.-W. (1988) · PubMed · Cited by 17
Benzoyl peroxide lotion (20 percent) in acne.
Smith, E. B., Padilla, R. S., Mccabe, J. M., & Becker, L. E. (1980) · PubMed · Cited by 16
STAINFORTH, J., MacDonald-Hull, S. P., Papworth-smith, J., et al. (1993) · Journal of Dermatological Treatment · doi:10.3109/09546639309080548 · Cited by 16
Topical Erythromycin for Acne vulgaris
Hellgren, L. I., & Vincent, J. (2009) · Dermatologica · doi:10.1159/000250399 · Cited by 15
Egan, N., Loesche, M. C., & Baker, M. (2001) · PubMed · Cited by 15
(1976) · PubMed · Cited by 14
Zhu, X. J., Tu, P., Zhen, J., & Duan, Y. (2001) · PubMed · Cited by 14
Comparison of tretinoin solution and benzoyl peroxide lotion in the treatment of acne vulgaris
Bucknall, J. H., & Murdoch, P. N. N. (1977) · Current Medical Research and Opinion · doi:10.1185/03007997709110177 · Cited by 13
Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis.
Nighland, M., & Grossman, R. (2008) · PubMed · Cited by 12
Lachnit-Fixson, U., & Kaufmann, J. (1977) · PubMed · Cited by 12
Retinoic acid cream (Airol cream) and benzoyl-peroxide in the treatment of acne vulgaris.
Handojo, I. (1979) · PubMed · Cited by 12
A novel gel formulation of clindamycin phosphate-tretinoin is not associated with acne flaring.
Leyden, J. J., & Wortzman, M. S. (2008) · PubMed · Cited by 11
BENZOYL PEROXIDE GEL THERAPY IN ACNE IN SINGAPORE
YONG, C. C. (1979) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1979.tb01955.x · Cited by 11
The effect of a phasic oral contraceptive containing Desogestrel on seborrhea and acne
Kränzlin, H. T., & Nap, M. A. (2006) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625180500252638 · Cited by 11
Alirezaï, M., Gerlach, B., Horváth, A., et al. (2005) · PubMed · Cited by 10
Bleeker, J., Hellgren, L. I., & Vincent, J. (2009) · Dermatologica · doi:10.1159/000250298 · Cited by 9
A Noninferiority Margin for Acne Lesion Counts
Gerlinger, C., Städtler, G., Götzelmann, R., Graupe, K., & Endrikat, J. (2008) · Drug Information Journal · doi:10.1177/009286150804200608 · Cited by 9
Bleeker, J. (1983) · Journal of International Medical Research · doi:10.1177/030006058301100108 · Cited by 9
Clinical and bacteriological evaluation of tetracycline and erythromycin in acne vulgaris.
Ma, A.-M. (1987) · PubMed · Cited by 8
Treatment of acne vulgaris with oral tetracyclines
Khanna, N. (1993) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 8
Evaluation of Triaz 10% Gel and Benzamycin in acne vulgaris
Sklar, J., Jacobson, C., Rizer, R. L., & Gans, E. (1996) · Journal of Dermatological Treatment · doi:10.3109/09546639609086876 · Cited by 8
Clindamycin phosphate 1% gel in acne vulgaris
Rizer, R. L., Sklar, J. L., Whiting, D., Bucko, A. D., Shavin, J. S., & Jarratt, M. (2001) · Advances in Therapy · doi:10.1007/bf02850194 · Cited by 7
Iaffé, G. V., Grimshaw, J., & Constad, D. (1989) · Current Medical Research and Opinion · doi:10.1185/03007998909115932 · Cited by 4
Cited by
Tuchayi, S. M., Makrantonaki, E., Ganceviciene, R., Dessinioti, C., Feldman, S. R., & Zouboulis, C. C. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.29 · Cited by 432
Self-citationThe epidemiology of acne vulgaris in late adolescence
Lynn, D., Umari, T., Dellavalle, R., & Dunnick, C. (2016) · Adolescent Health, Medicine and Therapeutics · doi:10.2147/ahmt.s55832 · Cited by 332
Systematic review of antibiotic resistance in acne: an increasing topical and oral threat
Walsh, T. R., Efthimiou, J., & Dréno, B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00527-7 · Cited by 314
Self-citationWhy Topical Retinoids Are Mainstay of Therapy for Acne
Leyden, J., Stein-Gold, L., & Weiss, J. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0185-2 · Cited by 164
Trends in oral antibiotic prescription in dermatology, 2008 to 2016
Barbieri, J. S., Bhate, K., Hartnett, K. P., Fleming-Dutra, K. E., & Margolis, D. J. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.4944 · Cited by 97
Metadata
- Authors
- Nast, A., Dréno, B., Bettoli, V., Degitz, K., Erdmann, R., Finlay, A. Y., Ganceviciene, R., Haedersdal, M., Layton, A., López‐Estebaranz, J. L., Ochsendorf, F., Oprica, C., Rosumeck, S., Rzany, B., Sammain, A., Simonart, T., Veien, N. K., Živković, M. V., Zouboulis, C. C., & Gollnick, H.
- Venue
- Journal of the European Academy of Dermatology and Venereology
- Publisher
- Wiley
- Published
- 2012-02
- Volume
- 26
- Issue
- s1
- Pages
- 1-29
- ISSN
- 0926-9959 (ISSN-L)
- 1468-3083
- OpenAlex
- W1693800702
- Cited by
- 426
- References
- 275
- FWCI
- 40.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.